热门资讯> 正文
Invivyd提供Pemgarda 2024净产品收入指导
2024-04-05 04:16
- Invivyd (NASDAQ:IVVD) announced that PEMGARDA is now available for purchase in the U.S. for pre-exposure prophylaxis of COVID-19 in certain adults and adolescents with moderate-to-severe immune compromise.
- The company provided PEMGARDA net product revenue guidance in the range of $150 million to $200 million for the full year 2024.
- Based on this anticipated net product revenue and our continued optimization of operating expenses, we expect to end 2024 with at least $55 million in cash and cash equivalents.
- Source: Press Release
More on Adagio Therapeutics
- Morgan Stanley ups Invivyd to overweight, cites FDA EUA decision
- Invivyd stock soars on FDA EUA for COVID-19 prophylaxis drug
- Seeking Alpha’s Quant Rating on Adagio Therapeutics
- Historical earnings data for Adagio Therapeutics
- Financial information for Adagio Therapeutics
推荐文章
新股首日 | “全球激光雷达龙头”禾赛-W涨逾7%！中签一手赚328港元
华盛早报 | 深夜大涨！谷歌市值突破3万亿美元大关；特朗普欲废除美股季报制度，改为仅披露半年报
9月16日外盘头条：马斯克增持10亿美元特斯拉股票 OpenAI推出新版GPT-5 特朗普敦促共和党团结 通过拨款法案
美股机会日报 | 特朗普怒斥：美联储主席能力不足！马斯克增持特斯拉后股价狂飙超8%
“三重利好”点燃特斯拉股价情绪！马斯克押宝Optimus机器人量产，这些概念也要爆？
新股暗盘 | “全球激光雷达龙头”禾赛-W涨近6%，中签一手账面浮盈248港元
港股异动 | 药捷安康上市不到3个月飙升超2000%，市值升破1100亿港元
外卖大战，战而不休为哪般？
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
